The Advanced Research Projects Agency for Health (ARPA-H) unveiled two nine-figure funding initiatives: THRIVE and GIVE. THRIVE focuses on accelerating design platforms for personalized gene editing treatments targeting rare hereditary diseases, while GIVE aims to develop localized, automated manufacturing units for producing individualized genetic medicines close to patients. This marks a pivotal step towards regulatory frameworks and broader availability of precision genetic therapies.